Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.
4.
6.

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.

Chapman TM, Perry CM.

Drugs. 2004;64(22):2577-95. Review.

PMID:
15516157
8.

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.

Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S; PREDICTIVE Study Group.

Curr Med Res Opin. 2008 Feb;24(2):369-76.

PMID:
18096110
9.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.
12.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.

13.

Defining the role of insulin detemir in Basal insulin therapy.

Morales J.

Drugs. 2007;67(17):2557-84. Review.

PMID:
18034591
14.

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.

Diabet Med. 2007 Jan;24(1):27-34.

PMID:
17227321
15.

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.

Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.

Diabet Med. 2008 Aug;25(8):916-23. doi: 10.1111/j.1464-5491.2008.02483.x.

PMID:
18959604
16.

Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.

Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.

Diabet Med. 2013 Feb;30(2):216-25. doi: 10.1111/dme.12041.

17.

Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.

Chapman TM, Perry CM.

BioDrugs. 2005;19(1):67-9.

PMID:
15691219
18.

An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.

Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.

Int J Clin Pract. 2010 Oct;64(11):1512-9. doi: 10.1111/j.1742-1241.2010.02391.x.

PMID:
20678116
19.

Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.

Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.

Diabetes Metab Res Rev. 2014 Jul;30(5):395-404. doi: 10.1002/dmrr.2500.

PMID:
24302583
20.

Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.

Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1326-35. doi: 10.1002/pds.3534. Epub 2013 Oct 21.

Supplemental Content

Support Center